...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research >The effect of teriparatide (human parathyroid hormone (1-34)) therapy on bone density in men with osteoporosis.
【24h】

The effect of teriparatide (human parathyroid hormone (1-34)) therapy on bone density in men with osteoporosis.

机译：特立帕肽（人甲状旁腺激素（1-34））治疗对骨质疏松症男性骨密度的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Teriparatide [rhPTH(1-34)] increases bone mineral density and reduces the risk of vertebral fracture in women. We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg. All subjects also received supplemental calcium and vitamin D. The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies. Biochemical markers of bone formation increased early in the course of therapy and were followed by increases in indices of osteoclastic activity. Spine bone mineral density was greater than in placebo subjects after 3 months of teriparatide therapy, and by the end of therapy it was increased by 5.9% (20 microg) and 9.0% (40 microg) above baseline (p < 0.001 vs. placebo for both comparisons). Femoral neck bone mineral density increased 1.5% (20 microg; p = 0.029) and 2.9% (40 microg; p < 0.001), and whole body bone mineral content increased 0.6% (20 microg; p = 0.021) and 0.9% (40 microg;p = 0.005) above baseline in the teriparatide subjects. There was no change in radial bone mineral density in the teriparatide groups. Bone mineral density responses to teriparatide were similar regardless of gonadal status, age, baseline bone mineral density, body mass index, smoking, or alcohol intake. Subjects experienced expected changes in mineral metabolism. Adverse events were similar in the placebo and 20-microg groups, but more frequent in the 40-microg group. This study shows that teriparatide treatment results in an increase in bone mineral density and is a potentially useful therapy for osteoporosis in men.
机译：特立帕肽[rhPTH（1-34）]增加女性的骨矿物质密度并降低椎骨骨折的风险。我们将437名脊椎或髋骨矿物质密度比年轻成年男性低2 SD的男性随机分配至每日注射安慰剂，特立帕肽20微克或特立帕肽40微克。所有受试者也都接受了钙和维生素D的补充。由于在常规毒理学研究中发现了大鼠的骨肉瘤，因此在中位持续11个月后停止了该研究。骨形成的生化标志物在治疗过程的早期增加，随后是破骨活性指数的增加。特立帕肽治疗3个月后，脊柱骨矿物质密度高于安慰剂受试者，到治疗结束时，脊柱矿物质密度比基线增加了5.9％（20 microg）和9.0％（40 microg）（p <0.001 vs.安慰剂两个比较）。股骨颈骨矿物质密度增加1.5％（20微克; p = 0.029）和2.9％（40微克; p <0.001），而全身骨矿物质含量增加0.6％（20微克; p = 0.021）和0.9％（40 microg; p = 0.005）在特立帕肽受试者中高于基线。特立帕肽组的radial骨矿物质密度没有变化。无论性腺状态，年龄，基线骨矿物质密度，体重指数，吸烟或饮酒情况如何，对特立帕肽的骨矿物质密度响应均相似。受试者经历了矿物质代谢的预期变化。安慰剂和20微克组的不良事件相似，但40微克组的不良事件更为频繁。这项研究表明，特立帕肽治疗可增加骨矿物质密度，是治疗男性骨质疏松症的潜在有用疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号